---
schema_version: "secwatch.filing_event.v1"
accession: "0001698530-26-000007"
form_type: "8-K"
ticker: "XCUR"
cik: "0001698530"
company_name: "EXICURE, INC."
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T08:47:49.883465+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Exicure achieves Phase 2 milestone for Burixafor (GPC-100); owes $1M payment to GPCR Therapeutics

## Summary
- Phase 2 trial (NCT05561751) completed; Clinical Study Report submitted to FDA on Jan 16, 2026.
- Milestone payment of $1,000,000 due to GPCR Therapeutics Inc. within 30 days.
- Achievement triggers improved future sublicensing income-sharing ratio for Exicure.
- Milestone reflects progress in development of small-molecule CXCR4 inhibitor Burixafor (GPC-100).

## SEC filing metadata
- accession: 0001698530-26-000007
- form_type: 8-K
- ticker: XCUR
- cik: 0001698530
- company_name: EXICURE, INC.
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1698530/000169853026000007/0001698530-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1698530/000169853026000007/xcur-20260116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001698530-26-000007
- JSON: https://secwatch.observer/filing/0001698530-26-000007.json
- Plain text: https://secwatch.observer/filing/0001698530-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.